TY - JOUR
T1 - Series: Pragmatic trials and real world evidence
T2 - Paper 2. Setting, sites, and investigator selection.
AU - Worsley, Sally D
AU - Oude Rengerink, Katrien
AU - Irving, Elaine
AU - Lejeune, Stephane
AU - Mol, Koen
AU - Collier, Sue
AU - Groenwold, Rolf H H
AU - Enters-Weijnen, Catherine
AU - Egger, Matthias
AU - Rhodes, Thomas
N1 - Publisher Copyright:
© 2017 The Authors
PY - 2017/8
Y1 - 2017/8
N2 - This second article in the series on pragmatic trials describes the challenges in selection of sites for pragmatic clinical trials and the impact on validity, precision, and generalizability of the results. The selection of sites is an important factor for the successful execution of a pragmatic trial and impacts the extent to which the results are applicable to future patients in clinical practice. The first step is to define usual care and understand the heterogeneity of sites, patient demographics, disease prevalence and country choice. Next, specific site characteristics are important to consider such as interest in the objectives of the trial, the level of research experience, availability of resources, and the expected number of eligible patients. It can be advisable to support the sites with implementing the trial-related activities and minimize the additional burden that the research imposes on routine clinical practice. Health care providers should be involved in an early phase of protocol development to generate engagement and ensure an appropriate selection of sites with patients who are representative of the future drug users.
AB - This second article in the series on pragmatic trials describes the challenges in selection of sites for pragmatic clinical trials and the impact on validity, precision, and generalizability of the results. The selection of sites is an important factor for the successful execution of a pragmatic trial and impacts the extent to which the results are applicable to future patients in clinical practice. The first step is to define usual care and understand the heterogeneity of sites, patient demographics, disease prevalence and country choice. Next, specific site characteristics are important to consider such as interest in the objectives of the trial, the level of research experience, availability of resources, and the expected number of eligible patients. It can be advisable to support the sites with implementing the trial-related activities and minimize the additional burden that the research imposes on routine clinical practice. Health care providers should be involved in an early phase of protocol development to generate engagement and ensure an appropriate selection of sites with patients who are representative of the future drug users.
KW - Pragmatic
KW - Real world
KW - Research naive
KW - Site selection
KW - Study design
KW - Trial
KW - Usual care
UR - https://www.scopus.com/pages/publications/85020759003
U2 - 10.1016/j.jclinepi.2017.05.003
DO - 10.1016/j.jclinepi.2017.05.003
M3 - Article
C2 - 28502811
SN - 0895-4356
VL - 88
SP - 14
EP - 20
JO - Journal of Clinical Epidemiology
JF - Journal of Clinical Epidemiology
ER -